Orphan Drug Designation Granted to Cereno Scientific’s CS1 for PAH
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
The U.S. FDA has granted orphan drug designation to CS1, Cereno Scientific’s lead therapy candidate for treating pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
Pulmonary arterial hypertension (PAH) is a rare type of pulmonary hypertension that can be the result of one of several causes, or by no apparent cause. Read more information about PAH here.| Pulmonary Hypertension News
Category archive page for News.| Pulmonary Hypertension News
